CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo

PLoS Pathog. 2019 May 30;15(5):e1007748. doi: 10.1371/journal.ppat.1007748. eCollection 2019 May.

Abstract

Epstein Barr virus (EBV) is one of the most ubiquitous human pathogens in the world, persistently infecting more than 90% of the adult human population. It drives some of the strongest human CD8+ T cell responses, which can be observed during symptomatic primary infection known as infectious mononucleosis (IM). Despite high viral loads and prolonged CD8+ T cell stimulation during IM, EBV enters latency and is under lifelong immune control in most individuals that experience this disease. We investigated whether changes in T cell function, as frequently characterized by PD-1 up-regulation, occur during IM due to the prolonged exposure to high antigen levels. We readily detected the expansion of PD-1 positive CD8+ T cells together with high frequencies of Tim-3, 2B4, and KLRG1 expression during IM and in mice with reconstituted human immune system components (huNSG mice) that had been infected with a high dose of EBV. These PD-1 positive CD8+ T cells, however, retained proliferation, cytokine production, and cytotoxic abilities. Multiple subsets of CD8+ T cells expanded during EBV infection, including PD-1+Tim-3+KLRG1+ cells that express CXCR5 and TCF-1 germinal center homing and memory markers, and may also contain BATF3. Moreover, blocking the PD-1 axis compromised EBV specific immune control and resulted in virus-associated lymphomagenesis. Finally, PD-1+, Tim-3+, and KLRG1+ CD8+ T cell expansion coincided with declining viral loads during low dose EBV infection. These findings suggest that EBV infection primes PD-1 positive CD8+ T cell populations that rely on this receptor axis for the efficient immune control of this ubiquitous human tumor virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / virology
  • Case-Control Studies
  • Cytokines / metabolism
  • Epstein-Barr Virus Infections / immunology*
  • Epstein-Barr Virus Infections / metabolism
  • Epstein-Barr Virus Infections / virology
  • Gene Expression Profiling
  • Herpesvirus 4, Human / immunology*
  • Humans
  • Inflammation Mediators / metabolism
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Programmed Cell Death 1 Receptor / metabolism*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Viral Load / immunology*

Substances

  • Cytokines
  • Inflammation Mediators
  • Programmed Cell Death 1 Receptor

Grants and funding

This study was financially supported by Cancer Research Switzerland (KFS-4091-02-2017 and KFS-4231-08-2017; https://www.krebsforschung.ch/), KFSP-MS, KFSP-PrecisionMS and KFSP-HHLD of the University of Zurich (https://www.uzh.ch/de/research/medicine/clinic.html), the Vontobel Foundation (https://www.vontobel-stiftung.ch/DE/Home), the Baugarten Foundation (https://www.baugarten-zuerich.ch/uber-uns/), the Sobek Foundation (https://mwk.baden-wuerttemberg.de/de/service/presse/pressemitteilung/pid/sobek-preis-verliehen-1/), the Swiss Vaccine Research Institute (http://swissvaccineresearchinstitute.ch/), the Swiss MS Society (https://www.multiplesklerose.ch/) and the Swiss National Science Foundation (310030_162560 and CRSII3_160708; http://www.snf.ch). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.